To assess the impact of the CytoSorb device during cardiopulmonary bypass compared to standard of care without CytoSorb. Measures include change in plasma free hemoglobin; assessment of device-related adverse events; time on ventilator; time in ICU; hospital stay; incidence of acute kidney injury; and others.